Bristol-Myers Squibb was named to Fortune’s World’s Most Admired Companies list as part of the magazine’s annual rankings. The company was No. 5 in the Pharmaceuticals category. The list is put together based on responses from thousands of survey participants. Fortune notes the companies featured on the World’s Most Admired list “represent the pinnacle of excellence in nine key performance areas, from investment value to social responsibility.”
With the help of the Bristol-Myers Squibb Foundation, the U.S. Department of Veterans Affairs is hoping to wage a war on lung cancer by increasing veterans’ access to lung cancer screenings across the country.
Sponsored by the Bristol-Myers Squibb Foundation, the project brings together a leading team of lung cancer experts and the VA to develop the VA-Partnership to increase Access to Lung Screening or VA-PALS. The goal is to develop early-detection programs for lung cancer, a malignancy with an 80 percent cure rate when caught early.
The initiative aims to create lung cancer screening programs at 10 VA medical centers throughout the U.S. to increase veterans’ access to lung cancer screenings with innovative technology designed for early detection.
The Merck Foundation (the Foundation) has launched a five-year initiative: Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap) to help improve diabetes care and health outcomes for vulnerable and underserved populations in the United States.
While we have seen global maternal deaths drop by 44% since 1990, women are still dying from preventable causes during pregnancy and childbirth – and not just in low and middle-income countries that lack resources. Even in high-income countries, there are women who face a much higher risk of death, or grave injury because they are poor, migrants, refugees, minorities or from indigenous populations.
Bristol-Myers Squibb Company (NYSE:BMY) has been named to the prestigious Dow Jones Sustainability Index (DJSI) North America for the third consecutive year. The 2017 North America Index is an independent validation of the important work the company is carrying out in the area of corporate responsibility and Bristol-Myers Squibb is one of three pharmaceutical, biotechnology and life sciences companies to earn a spot. Recognizing public companies for outstanding performance across economic, environmental and social factors, the Index serves as a benchmark for investors who integrate sustainability considerations into their portfolios.
Shire is the global leader in serving patients with rare diseases. We strive to develop innovative therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.
Did you know of 7,000 rare diseases, only 5% have treatments available?
On July 18th, Shire invited professionals local to Cambridge, MA to participate in Rare in Kendall Square: Collaborating to Advance Innovation in Rare Disease. Over 200 attendees gathered to network and weigh in on a panel discussion centered around the idea that partnerships can advance treatment options.
Pfizer believes its business and societal missions are the same: to ensure that all individuals everywhere have access to quality medicines, vaccines and healthcare, and the opportunity to lead healthy lives. Every day, the company strives to use its full resources – people, products and funding – to find new ways to positively impact the health of people around the world.
To speed the search to cure diseases, genomics leader HudsonAlpha Institute for Biotechnology generates enormous amounts of DNA data in its research labs. To tackle petabytes of information, they partnered with HPE to design flexible, high-performance systems and connectivity solutions that support intensive research, collaboration, and analysis. The powerful technology is helping HudsonAlpha’s scientists deliver on the tremendous promise of genomics to drive medical breakthroughs including ground-breaking research into Zika and other deadly diseases.
Novartis and the Ministry of Health of Uganda have signed a Memorandum of Understanding to implement Novartis Access in Uganda. Uganda becomes the fifth country to launch the Novartis Access program. Novartis Access medicines will be made available to patients in public health facilities through the National Medical Stores and through faith-based health services. The program will also cover capacity-building activities, including NCD prevention, diagnosis and treatment.
Corporate governance, risk management, operational integrity, and regulatory compliance are demanding challenges that companies face in today’s ever...
Through our Goals That Inspire we strive to make a positive difference in our communities by relying on our ability to understand their needs and then...
As sustainability leaders, we implement our sustainability strategy across all company activities along the entire value chain, from raw materials to...
